Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.

doi:10.1016/j.jtho.2025.05.012

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2025

Krebs Matthew G, Cho Byoung Chul, Hiret Sandrine, Han Ji-Youn, Lee Ki Hyeong, Pérez Casilda Llácer, De Braud Filippo, Haura Eric B, Sanborn Rachel E, Chih-Hsin Yang James, Shu Catherine A, Goto Koichi, Nishio Makoto, Zhao Jun, Wang Zhijie, Tomasini Pascale, Felip Enriqueta, Goldman Jonathan W, Ou Sai-Hong Ignatius, Boyer Michael, Gao Grace, Qu Siyang, Curtin Joshua C, Lyu Xuesong, Schnepp Robert W, Kim Priya, Thayu Meena, Knoblauch Roland E, Lorenzini Patricia, Baig Mahadi, Spira Alexander I, Leighl Natasha B

Abstract excerpt

INTRODUCTION: Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity. We assessed the safety and efficacy of amivantamab in participants with advanced NSCLC harboring primary MET exon 14 skipping mutations (METex14). METHODS: CHRYSALIS enrolled participants with METex14 NSCLC who progressed after or declined standard-of-care therapy. Participants received intravenous amivantamab weekly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Bispecific

Share to Antineoplastic Agents, Immunological

Share to Carcinoma, Non-Small-Cell Lung

Share to Exons

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins c-met

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 40383434
DOI: 10.1016/j.jtho.2025.05.012

Genes

MET
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.PMID 40383434Read ↗

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.Semantic proximity Read ↗

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.Semantic proximity Read ↗

Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.Semantic proximity Read ↗

Amivantamab Emerges Positively from Its "Chrysalis".Semantic proximity Read ↗

A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study.Semantic proximity Read ↗

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.Semantic proximity Read ↗

A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab.Semantic proximity Read ↗

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.Semantic proximity Read ↗

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.Semantic proximity Read ↗

[Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].Semantic proximity Read ↗

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.